Afficher la notice abrégée

dc.contributor.authorSantos García, Diego
dc.contributor.authorMir, Pablo
dc.contributor.authorCubo Delgado, Esther 
dc.contributor.authorVela Desojo, Lydia
dc.contributor.authorRodríguez Oroz, Mari Cruz
dc.contributor.authorMartí, María José
dc.contributor.authorArbelo, José Matías
dc.contributor.authorInfante, Jon
dc.contributor.authorKulisevsky Bojarsky, Jaume
dc.contributor.authorMartínez Martín, Pablo
dc.date.accessioned2024-03-07T13:31:37Z
dc.date.available2024-03-07T13:31:37Z
dc.date.issued2016-02
dc.identifier.urihttp://hdl.handle.net/10259/8777
dc.description.abstractBackground Parkinson’s disease (PD) is a progressive neurodegenerative disorder causing motor and non-motor symptoms that can affect independence, social adjustment and the quality of life (QoL) of both patients and caregivers. Studies designed to find diagnostic and/or progression biomarkers of PD are needed. We describe here the study protocol of COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), an integral PD project based on four aspects/concepts: 1) PD as a global disease (motor and non-motor symptoms); 2) QoL and caregiver issues; 3) Biomarkers; 4) Disease progression. Methods/design Observational, descriptive, non-interventional, 5-year follow-up, national (Spain), multicenter (45 centers from 15 autonomous communities), evaluation study. Specific goals: (1) detailed study (clinical evaluations, serum biomarkers, genetic studies and neuroimaging) of a population of PD patients from different areas of Spain, (2) comparison with a control group and (3) follow-up for 5 years. COPPADIS-2015 has been specifically designed to assess 17 proposed objectives. Study population: approximately 800 non-dementia PD patients, 600 principal caregivers and 400 control subjects. Study evaluations: (1) baseline includes motor assessment (e.g., Unified Parkinson’s Disease Rating Scale part III), non-motor symptoms (e.g., Non-Motor Symptoms Scale), cognition (e.g., Parkinson’s Disease Cognitive Rating Scale), mood and neuropsychiatric symptoms (e.g., Neuropsychiatric Inventory), disability, QoL (e.g., 39-item Parkinson’s disease Quality of Life Questionnaire Summary-Index) and caregiver status (e.g., Zarit Caregiver Burden Inventory); (2) follow-up includes annual (patients) or biannual (caregivers and controls) evaluations. Serum biomarkers (S-100b protein, TNF-α, IL-1, IL-2, IL-6, vitamin B12, methylmalonic acid, homocysteine, uric acid, C-reactive protein, ferritin, iron) and brain MRI (volumetry, tractography and MTAi [Medial Temporal Atrophy Index]), at baseline and at the end of follow-up, and genetic studies (DNA and RNA) at baseline will be performed in a subgroup of subjects (300 PD patients and 100 control subjects). Study periods: (1) recruitment period, from November, 2015 to February, 2017 (basal assessment); (2) follow-up period, 5 years; (3) closing date of clinical follow-up, May, 2022. Funding: Public/Private. Discussion COPPADIS-2015 is a challenging initiative. This project will provide important information on the natural history of PD and the value of various biomarkers.en
dc.description.sponsorshipThe project funding is both public and private. There will be an ambitious campaign (COPPADIS Social Project; www.coppadis.com and curemoselparkinson.org) designed to have a huge social impact, developed under a clear and unique concept to engage society.en
dc.format.mimetypeapplication/pdf
dc.language.isoenges
dc.publisherSpringer Natureen
dc.relation.ispartofBMC Neurology. 2016, V. 16, n. 1en
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectBiomarkersen
dc.subjectCaregiveren
dc.subjectGenetic studiesen
dc.subjectResonance imagingen
dc.subjectNon-motor symptomsen
dc.subjectParkinson’s diseaseen
dc.subjectProgressionen
dc.subjectQuality of lifeen
dc.subject.otherSistema nervioso-Enfermedadeses
dc.subject.otherNervous system-Diseasesen
dc.subject.otherMedicinaes
dc.subject.otherMedicineen
dc.titleCOPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015), a global –clinical evaluations, serum biomarkers, genetic studies and neuroimaging– prospective, multicenter, non-interventional, long-term study on Parkinson’s disease progressionen
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.relation.publisherversionhttps://doi.org/10.1186/s12883-016-0548-9es
dc.identifier.doi10.1186/s12883-016-0548-9
dc.identifier.essn1471-2377
dc.journal.titleBMC Neurologyen
dc.volume.number16es
dc.issue.number1es
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Fichier(s) constituant ce document

Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée